Nuvation Bio (NUVB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Is Nuvation Bio (NYSE:NUVB) Using Too Much Debt?
Simply Wall StNov 21 10:58 ET
Nuvation Bio's Q3 2024 Highlights and Future Prospects
TipRanksNov 20 22:53 ET
Nuvation Bio to Present at the Jefferies London Healthcare Conference
BusinesswireNov 12 16:05 ET
Top 4 Health Care Stocks That May Plunge This Quarter
BenzingaNov 11 06:18 ET
Nuvation Bio Is Maintained at Outperform by RBC Capital
Dow JonesNov 7 12:27 ET · Ratings
Nuvation Bio Analyst Ratings
BenzingaNov 7 12:15 ET · Ratings

Comments

Jaguar8

Sep 15 19:34

WEEKEND NEWS

$Nuvation Bio (NUVB.US)$
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Nuvation Bio (NYSE: NUVB) announced positive pooled data from TRUST-I and TRUST-II studies evaluating taletrectinib, a next-generation ROS1 TKI for advanced ROS1-positive NSCLC. Key findings include:
- 89% tumor shr...

2

Clintzilla

Sep 15 08:02

$Nuvation Bio (NUVB.US)$ big arse float but on watch

Trytosaveabit

Jun 26 16:16

Insider buy! Or should I say MORE buys! Hehehe

$Nuvation Bio (NUVB.US)$ Director Cui Xiangmin purchased 277.9K shares of common stock on Jun 25, 2024 at an average price of $2.97 for a total value of $825.35K.

17

Trytosaveabit

Jun 25 17:33

Insider buy

$Nuvation Bio (NUVB.US)$ Director Cui Xiangmin purchased 500K shares of common stock on Jun 20, 21, 24, 2024 at an average price of $2.98 for a total value of $1.49 million.

1

3

Trytosaveabit

Jun 3 04:00

Watching!

$Nuvation Bio (NUVB.US)$ Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of t...

1

NUVB Nuvation Bio

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target